Minimal residual disease analysis in acute lymphoblastic leukemia of childhood after an induction therapy without asparaginase;Minimal residual disease untersuchungen bei der akuten lymphatischen Leukamie im kindesalter im rahmen der coall-studie: Ergebnisse einer induktionstherapie ohne asparaginase

Klinische Padiatrie

Volumn 212, Issue 4, 2000, Pages 169-173

  Zur Stadt, U ^a   Harms, D O ^a   Schluter, S ^a   Jorch, N ^b   Spaar, H J ^c   Nurnberger, W ^d   Volpel, S ^e   Gutjahr, P ^f   Schrappe, M ^g   Janka, G ^a   Kabisch, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Gilead Hospital   (Germany)

^c Zentralkrankenhaus   (Germany)

^d Universitatskinderklinik Dusseldorf   (Germany)

^e Kinderklinik Klinikum Krefeld   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g Abt für pädiatrische matologie und Onkologie   (Germany)

Author keywords

Asparaginase; COALL; Induction therapy; MRD

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFICACY; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PROGNOSIS; SCHOOL CHILD; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME;

EID: 0033848046     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9672     Document Type: Article

References (13)

1. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction
2. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
3. An improved method for detection of B-lymphoid clonality by polymerase chain reaction
4. Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification
5. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis
6. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
7. In vitro drug resistance as independent prognostic factor in the study COALL-05-92 Treatment of childhood acute lymphoblastic leukemia; two- tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97
8. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
9. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia
10. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia
11. Genetic abnormalities and drug resistance in acute lymphoblastic leukemia
12. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
13. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood